KeyGene and Guardant Health extend licensing agreement
April 21, 2020
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics and Keygene N.V., a leading AgroFood biotech company focusing on crop innovation research, have signed an extended worldwide, non-exclusive license agreement with respect to Next Generation Sequencing technologies of KeyGene.